Jaffer A. Ajani

Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction

John S. Macdonald, Stephen R. Smalley, Jacqueline Benedetti et al. · New England Journal of Medicine · 2001 · 3.5K citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.7K citations · Full text

Chemotherapy Versus Chemotherapy, Esophageal Cancer, Gastrointestinal Oncology +7

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.4K citations

Surgical Oncology, Gastrointestinal Oncology, Medicine +7

Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group

Eric Van Cutsem, Vladimir Moiseyenko, Sergei Tjulandin et al. · Journal of Clinical Oncology · 2006 · 1.9K citations · Full text

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text